Skip to content

Curation log — lung-squamous-cell-carcinoma

2026-08-28 — Seed session

  • What changed: Condition seeded: INDEX.md (portrait + 17-page proposed canonical list, sibling cross-reference to lung-adenocarcinoma), wiki/overview.md (draft, 19 PMID-verified references), OPEN-QUESTIONS.md (7 seed questions), this log.
  • What was searched: Live PubMed queries on: TCGA 2012 squamous characterization, FGFR1 amplification (Weiss 2010), Lung-MAP master protocol, CheckMate 017, KEYNOTE-407 (primary + 5-yr update), KEYNOTE-024, CheckMate 816, pemetrexed histology interaction, squamous therapeutic-landscape reviews (Langer 2016; Yuan 2021), plus the shared screening set (NLST, NELSON, USPSTF 2021), classification (Travis 2011), testing guideline (Lindeman 2018), never-smoker genomics (Díaz-Gay 2025), and population mortality (Howlader 2020) — verified once this session and shared with the adenocarcinoma sibling. All PMIDs verified via search + metadata retrieval this session.
  • Check next time: (1) DDR2 mutation and PI3K-pathway trial outcomes for failed-and-frontier-targets.md; (2) necitumumab SQUIRE and ramucirumab REVEL primary papers (currently only covered via the Langer 2016 review); (3) CheckMate 227/9LA (IO-doublet regimens including squamous patients); (4) squamous-subset results of perioperative IO trials; (5) TROP2/other ADC trials in squamous disease; (6) histology-stratified screening performance data.

2026-08-29 — Full build

  • What changed: Completed all 17 canonical wiki pages and replaced the seeded overview. Built literature/BIBLIOGRAPHY.md, six landmark-study notes, guidelines/REGISTRY.md, statistics/STATISTICS.md, and the four-file patient-voice layer. Rewrote OPEN-QUESTIONS.md as a tiered, study-shaped agenda with a 12-row “Dots not yet connected” table; updated the master index and roadmap status.
  • PubMed work: Ran live PubMed E-utilities searches across burden and exposures; airway premalignancy; pathology and mimics; screening; TNM/staging; TCGA and later multi-omic/spatial biology; FGFR, DDR2, PI3K, cell-cycle, redox and ADC programs; chemotherapy; immunotherapy; perioperative and stage-III therapy; biomarkers; safety; palliative care; stigma; caregivers; financial toxicity; patient-reported outcomes; and trial participation. Performed a final ESummary re-query of every unique PMID used in the wiki and generated the bibliography from returned metadata. The wiki contains 321 unique PubMed records; no PMID was accepted from memory.
  • ClinicalTrials.gov work: Queried the current v2 API record for all 25 NCT identifiers used: NCT01642004, NCT02125461, NCT02154490, NCT02486718, NCT02504372, NCT02775435, NCT02785913, NCT02965378, NCT02998528, NCT03373760, NCT03425643, NCT03800134, NCT04025879, NCT04225117, NCT04310007, NCT04497584, NCT04966663, NCT05255302, NCT05613413, NCT05902520, NCT07221474, NCT07249372, NCT07459751, NCT07489066, and NCT07638891. Registry status was kept separate from published efficacy.
  • Important corrections: Replaced incorrect ninth-edition TNM identifiers with PMIDs 38447919 and 38885896; replaced an incorrect Lung-MAP design identifier with PMID 26408303; removed the seeded unsupported claim of roughly 400,000 annual LUSC deaths and used modelled 2022 incidence (616,769 cases; PMID 39914442) with an explicit mortality-data limitation. Final title-to-claim QA also caught four mis-mapped PMIDs in the statistics/open-question extraction and replaced them with the live-query-confirmed records: dovitinib 27315356, AZD4547 31195180, TAK-228 36240971, and postoperative complications 38975138.
  • Evidence boundaries: Labelled NSCLC-wide results rather than implying LUSC-specific effects; treated mechanistic targets as hypotheses unless clinically validated; preserved exploratory/subgroup qualifiers; separated relative from absolute effects; and described registry records as mutable sponsor-entered data.
  • Patient voice: Used only public organizational pages and PubMed-indexed research; no private communities, composite quotations, or cross-source patient dossiers. The main limitation is the scarcity of qualitative research stratified specifically by squamous histology and the geographic concentration of published evidence.
  • Next update triggers: New ASCO living-guideline version or jurisdictional authorization; ninth-edition TNM implementation data; overall-survival maturity for perioperative trials; randomized evidence isolating the postoperative checkpoint component; a practice-changing LUSC ADC/redox/FGFR result; definitive post-chemo-immunotherapy sequence data; or a new global histology-specific burden release.
  • Validation: Confirmed 17 canonical wiki files, each 150–400 lines and 25–60 unique PubMed plus ClinicalTrials.gov identifiers; 322 unique condition-wide PMIDs fully covered by the bibliography; 25 unique NCT IDs live-queried; all local Markdown links resolved; no stale scaffold markers, temporary build files, or non-Markdown artifacts remained in the condition directory. Validation matched PMID labels to destination URLs and included title-to-claim review, so an existent but unrelated PubMed record could not pass merely by resolving.

2026-08-30 — Full audit

  • Scope checked: Audited every one of the 17 canonical wiki pages and every literature artifact: the 326-entry master bibliography, six landmark notes, guideline registry, statistics ledger, four-file patient-voice layer, open-question agenda, index, and prior curation log. The final wiki pages remain 153–247 lines each and contain 25–36 unique PMID plus NCT identifiers each.
  • Live PubMed verification: Re-extracted all identifiers from the finished condition corpus and submitted all 326 unique PMIDs to PubMed E-utilities EFetch during this audit session. All 326 resolved. Checked 765 full reference lines across the wiki reference sections and master bibliography against returned first-author and title metadata; the final check produced zero author/title mismatches. Every PMID used by a literature artifact is present in the bibliography, and the bibliography's canonical-wiki cited by mappings have zero missing or stale mappings.
  • Live registry verification: Submitted every one of the 29 unique NCT identifiers in the finished corpus to the ClinicalTrials.gov API v2 during this audit session; all 29 resolved. This includes the 25 treatment-trial identifiers already catalogued on the trials page and four anti-stigma studies added while correcting a stale evidence-gap claim (NCT05456841, NCT06191939, NCT03750864, NCT06286592). Registry state is dated 2026-08-30 and remains separated from published efficacy.
  • Citation errors found and fixed: Canonicalized 438 pre-existing abbreviated wiki references to the live PubMed metadata, including 62 detected wrong first-author attributions. Replaced PMID 17167000 as support for post-obstructive infection because that paper concerns outcomes after central-airway-obstruction treatment, not pneumonia; the infection claim now uses the live-verified cancer post-obstructive-pneumonia review PMID 29392577. Added primary TCGA support (PMID 22960745) to the 72% CDKN2A/RB1-pathway prevalence claim instead of leaving the negative palbociclib trial as its only citation. No wrong citation or unresolved claim remains flagged.
  • Stale-absence searches: Re-ran PubMed and ClinicalTrials.gov searches for redox-directed therapy, durable LUSC immunotherapy prediction, bronchial-premalignancy risk models/interception, postoperative checkpoint component isolation, central-airway patient-reported scales, histology-specific global mortality, digital-community outcomes, and stigma interventions. Converted genuine gaps into positively stated, dated search findings. Corrected the outdated implication that stigma interventions do not exist: a 2024 systematic review found 11 mostly pilot studies (PMID 39197098), a communication-training pilot reported provider-level changes (PMID 38836528), and four registry studies confirm an intervention pipeline; the remaining gap is adequately powered evidence for diagnostic interval, treatment uptake, or survival. Added 2026 retrospective pCR evidence (PMID 42055888; DFS HR 1.22, 95% CI 0.51–2.95) while preserving the narrower conclusion that no randomized study isolates the postoperative component.
  • Mutable sources: Rechecked all 25 treatment-trial records, the four added stigma-trial records, the guideline sources available without authentication, and the five public patient-organization pages. Updated registry, guideline, patient-source, and evidence-cutoff dates to 2026-08-30. Retained the NCCN authenticated-access caveat rather than inferring a version from a secondary source.
  • Final QA and disposition: All 17 wiki pages passed: 326/326 PMIDs resolved, 29/29 NCT IDs resolved, 0 reference-metadata mismatches, 0 bibliography-mapping failures, 0 broken local links, and 0 unverified flags. Every wiki page was therefore promoted to status: curated; literature assets are marked audited in the index, and the condition roadmap is now audited. Remaining substantive flags: none. Evidence gaps remain explicitly labelled as dated gaps rather than unresolved verification failures.

2026-08-31 — Completion audit of the remaining eight pages

  • Scope and disposition: Independently re-audited the eight pages identifiable as the unfinished 9/17 split: biomarkers.md, clinical-trials-landscape.md, early-stage-and-perioperative-therapy.md, guidelines.md, overview.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, and systemic-therapy.md. The on-disk frontmatter had already been changed to curated before this pass, so those declarations were treated as untrusted until the checks below passed. All eight now pass and remain status: curated; combined with the nine pages that passed the earlier audit, all 17 canonical pages pass.
  • Live PubMed verification: Extracted the final eight-page identifier set and fetched all 153 unique PMIDs through PubMed E-utilities in this session. All 153 resolved. Reviewed 226 inline PMID links across 120 cited claim blocks against the fetched titles and abstracts, including every quoted effect size, sample size, confidence interval, and event rate. Final automated reference QA found 0 first-author mismatches, 0 title mismatches, 0 PMID label/URL mismatches, and 0 unresolved records.
  • Live ClinicalTrials.gov verification: Fetched all 23 unique NCT records used by the final pages individually through the API v2 in this session; all 23 resolved. Rechecked overall status, enrollment type/count, phase, histology/condition, interventions, primary endpoints, country count where stated, and last-update date. Also reran active-registry searches for squamous NSCLC, Lung-MAP, NFE2L2/KEAP1, FGFR, TROP2, ctDNA-guided resected disease, ECOG 2 disease, stigma interventions, and central-airway patient-reported outcomes.
  • Registry errors fixed: Corrected the description of NCT04310007. Despite its generic NSCLC title and Lung-MAP relationship, the current record is restricted to non-squamous NSCLC and is not an active LUSC option. Added the directly relevant, not-yet-recruiting PANKU-Lung05 phase II/III study (NCT07739199; 200 estimated participants), while preserving that both arms contain the investigational PD-1/VEGF bispecific and that the phase III primary endpoint is PFS. Updated all registry/access dates to 2026-08-31 and removed the page's inconsistent 29/30 August wording.
  • Citation and claim repairs: Added ten full PubMed references that were cited inline but missing from the clinical-trials page reference list and two missing from the patient-experience page. Connected four previously reference-only systemic-therapy papers to the claims they support: KEYNOTE-024 for PD-L1-high monotherapy (PMID 27718847), nab-paclitaxel response by histology (PMID 22547591), cisplatin/gemcitabine versus cisplatin/pemetrexed in squamous disease (PMID 18506025), and the selected bevacizumab phase III bleeding/exclusion evidence (PMID 17167137). Final inline/reference sets are identical on every audited page, with no unused reference entries.
  • Overstatement and mutable-source repairs: Replaced the unsupported assertion that the ASCO web guideline was version 2026.3.3 with the live PubMed-verified 2026.3.1 publication (PMID 42190141); the ASCO landing page returned HTTP 403 during this audit, so the page now states that limitation and requires version rechecking at use. Softened “no cross-trial comparison” of postoperative checkpoint therapy to the accurate claim that no randomized comparison isolates the postoperative component and that indirect comparisons remain confounded. Removed the Lung Cancer Research Foundation resource row because its cited page and site root returned HTTP 403 and its resource description could not be re-verified; the other listed patient-organization pages returned HTTP 200.
  • Stale-absence searches: Reran live PubMed searches for randomized ctDNA-guided escalation/de-escalation after NSCLC resection, randomized isolation of adjuvant checkpoint therapy after neoadjuvant chemo-immunotherapy, LUSC-specific qualitative patient experience, histology-specific global mortality, serum-marker screening outcomes, post-chemo-immunotherapy LUSC sequencing, stigma interventions with clinical endpoints, and central-airway LUSC patient-reported measures. Reran corresponding ClinicalTrials.gov searches. No randomized PubMed record was found for ctDNA-guided resected-NSCLC treatment or post-chemo-immunotherapy LUSC sequencing; perioperative searches found combined-pathway trials and indirect comparisons, not randomized isolation of the postoperative component. The qualitative search produced seven raw hits but no inspected record directly supplied a LUSC-specific qualitative experience study. Stigma is not an empty field: added the 11-study systematic review (PMID 39197098) and 30-clinician Nigerian communication-training pilot (PMID 38836528), while retaining the narrower gap in patient outcomes, diagnostic interval, treatment uptake, and adequately powered randomized evidence.
  • Non-PubMed source checks: NICE NG122 and its cited diagnosis, management, suspected-cancer, and palliative-care pages; the USPSTF recommendation; IASLC molecular-testing resource; GO2 stigma/help-line pages; LUNGevity patient hub; and Roy Castle site all resolved live. The ACS web page returned HTTP 406, so its eligibility statement is supported only by the live PubMed guideline record (PMID 37909877), not asserted as a separately retrieved web citation.
  • Final QA: All eight pages are 153–247 lines. Final checks found 17 canonical pages, 0 draft statuses, 0 unresolved verification markers, 0 broken local links, 0 bibliography mapping failures, and 0 citation/reference set differences. The roadmap remains audited, with the completion date advanced to 2026-08-31. Remaining substantive flags: none. The ASCO web-version access block is an explicitly documented update-at-use limitation, not an unsupported content claim.

2026-10-10 — Literature sweep (Claude)

Author: Claude (claude-opus-5-5). This is the first periodic sweep since the 2026-08-31 completion audit. Every page this sweep edited has been demoted to draft. A different engine must audit those edits, because this entry's author also wrote them.

Window and method. The publication window was 2026-08-28 → 2026-10-10 by Entrez date. PubMed was queried directly through E-utilities; the PubMed MCP connector was not used. I ran 20 searches:

  • 17 windowed topic searches covering:
  • all LUSC
  • RCT/phase III
  • systematic reviews
  • guidelines
  • Cochrane
  • immunotherapy
  • perioperative therapy
  • ADC/FGFR/PIK3CA/NFE2L2/KEAP1 targets
  • molecular
  • screening/premalignancy
  • chemotherapy/antiangiogenics
  • biomarkers/ctDNA
  • epidemiology/smoking
  • diagnosis/histology
  • staging
  • patient experience/QoL
  • red flags
  • One named-trial search (AEGEAN, KEYNOTE-671, TROPION, HARMONi, ivonescimab and others).
  • One Cochrane search for 2025–2026.
  • One check of 2026 ASCO living-guideline versions.

I screened 440 unique PMIDs by title, read about 30 abstracts, and kept 13 records. Query strings, PubMed translations and returned PMIDs are in literature/sweeps/2026-10-10.json.

Sources actually queried.

Source Queried Notes
PubMed (E-utilities) yes 20 searches (above); retraction flags re-checked on all 326 previously cited PMIDs, none flagged
Cochrane, via "Cochrane Database Syst Rev"[jour] yes No lung-cancer review in the window. The 2025–2026 search found one review the build missed (below), plus two protocols without results (perioperative immunotherapy network meta-analysis, PMID 40386901; anti-TIGIT, PMID 40226904)
Europe PMC REST yes 236 hits: 171 MEDLINE, 21 PMC-only, 8 preprints, no conference abstracts. None survived triage (all preclinical, bioinformatic or off-topic)
Crossref yes updated-by checked on every added record. None flagged. The two Chinese Medical Association DOIs returned 404, so those were checked in PubMed only
ClinicalTrials.gov API v2 yes All 30 cited NCT records re-fetched. Also searched new squamous registrations (first posted ≥2026-08-28: 14) and newly posted results (2, neither relevant)
jRCT (Japan) yes jRCTs051200138 (WJOG14120L): complete, target n=45
NICE NG122 yes Unchanged since 2024-03-08
ASCO living-guideline web page blocked HTTP 403
Patient-organisation pages yes GO2 (×2), LUNGevity, Roy Castle: 200. LCRF patient page: still 403, as recorded in the 2026-08-31 audit
WHO ICTRP no JS portal
Cochrane Library / CENTRAL no HTTP 403
SciELO / LILACS no HTTP 403
Unpaywall skipped LIFEBANK_CONTACT_EMAIL unset, so no email was sent to Crossref either

Every absence below is an absence in the named source only.

What was found, in order of importance

  1. A Cochrane review missed by the build and both audits. Plissonneau 2026 (PMID 42440312; published July 2026, search to 2025-07-03) covers perioperative checkpoint inhibitors in adults ≥65: 11 RCTs, 3,152/6,788 participants aged ≥65.
  2. OS HR 0.88 (0.61–1.26; moderate certainty); EFS HR 0.61 (0.52–0.71); DFS HR 0.85 (0.73–0.99); pCR RR 5.07 (low certainty).
  3. No age-specific quality-of-life data, and too few data for the ≥75 or PD-L1 strata.
  4. It does not contradict the wiki, which made no age-specific perioperative claim. It fills a gap the wiki had not addressed.
  5. → early-stage-and-perioperative-therapy.md (paragraph and new open question 6), OQ-9, STATISTICS.
  6. AEGEAN updated outcomes (Heymach 2026, PMID 42664473): EFS HR 0.69 (0.55–0.88), DFS HR 0.66, interim OS HR 0.89 (0.70–1.14, not significant). → early-stage table row, STATISTICS. Not added to the guidelines or overview pages, whose AEGEAN statements remain accurate.
  7. WJOG14120L (Yoshioka 2026, PMID 42816458). This is the first prospective post-ICI data for cisplatin/gemcitabine/necitumumab in LUSC: n=46, ORR 26.1%, missing its 40% target; median PFS 4.4 and OS 12.2 months; no pneumonitis.
  8. It sharpens OQ-4 but does not answer it, because the study is single-arm.
  9. → chemotherapy-and-histology-constraints.md, clinical-trials-landscape.md, OQ-4, STATISTICS.
  10. FIND erdafitinib (Nogova 2026, PMID 42848441). In FGFR-altered NSCLC (73% squamous), 44,537 patients were screened to enrol 26. Fusions gave 2/7 PRs (one unconfirmed); mutations gave stable disease at best. → failed-and-frontier-targets.md (table row and paragraph), OQ-1, STATISTICS.
  11. HPV, p16 and Rb in primary vs metastatic lung SCC (Narutomi 2026, PMID 42758332). High-risk HPV was found in 0/114 primaries vs 9/11 metastases, and the p16+/Rb-partial-loss pattern occurred only in HPV-positive metastases. This extends the p16 caveat on the histology page. → histology-and-diagnosis.md, STATISTICS.
  12. Registry changes.
  13. IMpower010 (NCT02486718) is now Completed (actual 2026-08-26); the page had said active, not recruiting.
  14. Symbiotic-Lung-10 (NCT07489066) now lists 11 countries; the page said five.
  15. NCT04310007 is still restricted to non-squamous disease.
  16. Two new squamous registrations were added:
    • 7MW3711 vs docetaxel after chemo-IO: phase III, n=600, OS primary, China, not yet recruiting (NCT07831863). The registry does not state the agent's mechanism, and none was inferred.
    • Zanzalintinib plus pembrolizumab first-line maintenance: single-arm phase II, n=60 (NCT07845786).
  17. I first called NCT07831863 the "first" such randomized trial, then found that HLX43 ± HLX07 (NCT07459751, already cited) also requires prior platinum plus anti-PD-(L)1 and corrected the claim.
  18. All other cited statuses matched the live registry.
  19. Guidelines.
  20. New in REGISTRY: AATS 2026 revised early-stage consensus (PMID 42790620), Chinese Medical Association lung-cancer guideline 2026 (PMID 42764215), and Chinese NSCLC molecular-testing guideline 2026 (PMID 42851192; adds MTAP and SMARCA4 deletion as extended tests). Only abstracts were read.
  21. ASCO version hazard clarified, not resolved. In PubMed the newest without-driver version is still 2026.3.1. The PubMed record labelled 2026.3.3 (PMID 42607282) is the with-driver guideline. REGISTRY's "living version 2026.3.3" for the without-driver guideline could not be re-checked because the web page returned 403. I left it in place with a warning, not deleted.
  22. Bibliography-only additions (no wiki edits):
  23. squamous-only PD-(L)1 + chemotherapy meta-analysis (14 RCTs, OS HR 0.73; PMID 42724878; also in STATISTICS)
  24. KLF4/KRT13 hillock-like state in LUSC (PMID 42314152)
  25. smoke-exposed organoid stem-cell states (PMID 42832683)
  26. NCDB stage IA LUSC sublobar vs lobectomy (n=207, hypothesis-generating; PMID 42724670)
  27. AdvanTIG-105 sqNSCLC cohort (phase I, ORR 55.0%, n=40 evaluable; PMID 42785919)

Triaged out: - many single-centre bioinformatic and preclinical LUSC papers - non-squamous trials - KEYNOTE-671 Japanese subgroup (n=82) - AEGEAN by surgery type - neoadjuvant serplulimab observational study (n=30) - QL1706 neoadjuvant protocol - Xihu district (China) histology incidence trends: one district registry, not a burden estimate - Park 2026 smoking × histology prognosis: interaction not significant - CAN-2409 phase 2a: histology not separated in the abstract

Pages changed (all → status: draft, dated 2026-10-10): - failed-and-frontier-targets - chemotherapy-and-histology-constraints - histology-and-diagnosis - early-stage-and-perioperative-therapy - clinical-trials-landscape

Three pages use last_reviewed rather than last-curated in their frontmatter, and that key was updated instead. Their evidence_cutoff was left at 2026-08-31.

Other files updated: - BIBLIOGRAPHY: 17 records added, 343 total. That is the 13 kept records, plus the two ASCO with-driver versions cited in the REGISTRY version note and the two Cochrane protocols named in this entry - STATISTICS: 7 rows added; demoted to draft - REGISTRY - OPEN-QUESTIONS: OQ-1, OQ-4 and OQ-9 updated; none closed - INDEX: statuses

New file: literature/sweeps/2026-10-10.json.

Next sweep should chase: 1. The without-driver ASCO living version: confirm or correct "2026.3.3" from the ASCO site or a new PubMed record. 2. Whether TROPION-Lung07/08 or other ADC trials report squamous subgroups. 3. HLX43 (NCT07459751) and 7MW3711 (NCT07831863) recruitment and results. 4. AEGEAN final OS. 5. Whether the Cochrane perioperative-immunotherapy network meta-analysis (protocol PMID 40386901) and the anti-TIGIT review (protocol PMID 40226904) publish results. 6. FIND stage II. 7. Whether the auditor wants the KRT13 hillock paper on molecular-landscape.md. 8. Pre-existing and untouched here: the LCRF 403 URL still present in the patient-voice layer.

2026-10-17 — Periodic literature sweep (Codex)

Author: Codex. This is a literature sweep and mechanical validation, not an independent audit. All ten changed content files carry status: draft and last-curated: 2026-10-17; the log is append-only. Guidelines and screening join the five previously drafted wiki pages, leaving seven canonical pages awaiting a different engine's audit. No treatment recommendation changed and no open question was closed.

Window and searches. Used the requested 2026-08-28 through 2026-10-17 publication-date window, rather than advancing the lower bound to the previous sweep. Ran 34 PubMed E-utilities topic searches: one ordinary search and one "Cochrane Database Syst Rev"[jour] search for each of the 17 canonical topics. These covered overview; epidemiology/smoking; central airways/premalignancy; diagnosis; screening; staging; molecular biology; frontier targets/ADCs; immunotherapy; chemotherapy; early/perioperative and stage-III treatment; systemic sequencing; biomarkers; guidelines; trials; patient experience; and safety. Six supplementary E-utilities searches checked ASCO versions, ESMO/Pan-Asian publications, the prior Cochrane protocols/review, all lung-related in-window CDSR records, named trial follow-ups, and the LUNGevity assessment-schedule publication.

The topic queries returned 3,300 unique identifiers, fetched as 3,293 journal records and seven book records. These are retrieval counts, not a claim to have fully reviewed 3,300 sources. Title triage prioritized the 96-hit direct LUSC set and selected broader NSCLC randomized trials, reviews and guidelines, followed by abstracts/metadata for candidates. High-recall searches included substantial off-topic material. PubMed publication dates include in-window print issue dates even for papers published electronically before 28 August; that explains the earlier online dates of some additions. The exact queries, PubMed translations, returned IDs and selected-record checks are in the search manifest.

Sources actually queried and limits.

Source What was done Finding / boundary
PubMed E-utilities 34 topic/CDSR searches plus six follow-up searches; EFetch metadata/abstracts and publication types Four papers selected for catalogue/retrieval follow-up; no new quantitative paper extraction
Cochrane reviews through PubMed CDSR query per topic, plus a broad in-window lung/NSCLC CDSR query and prior-protocol retrieval No relevant completed new review selected. The returned broad-window reviews concerned menopausal hormone therapy and fetal neuroprotection, not LUSC treatment. Prior perioperative-immunotherapy and anti-TIGIT protocol records were re-fetched; no completed successor was selected
Europe PMC REST A publication-window query for each of the same 17 topics, including non-MEDLINE source types; 11,273 unique records retrieved across overlapping broad queries Used for candidate discovery and full-text availability. No EPMC-only record was selected for addition; this does not establish an absence of relevant non-MEDLINE literature. All four added journal records were labelled subscription-required at their DOI full-text links
Crossref REST DOI lookup, title/identifier matching and updated-by checks on all four added papers and the two ASCO version records used in the correction All six resolved; no retraction/expression-of-concern update returned. No owner email/contact address was sent
ClinicalTrials.gov API v2 Re-fetched all 32 previously cited records; searched new registrations and first-posted results in the window; additionally retrieved S1914 and the NLST record for publication follow-ups All 32 matched their most recent stored status, enrollment, hasResults, results-first-post and last-update fields. For 30, baseline was the prior cited-record snapshot; the two additions were compared with that sweep's registration summaries. No prior full outcome-table snapshot exists, so this is not a numerical outcome-by-outcome diff
ClinicalTrials.gov discovery searches 15 new-registration hits and two results-first-post hits The additional registration since 10 October was non-squamous. The two results records were broad early-phase oncology/NSCLC studies; no LUSC-specific outcome was selected for synthesis. An attempted ResultsLastUpdatePostDate advanced filter returned HTTP 400; it is recorded as failed, not as a successful results-update search. Tracked-record update dates and results fields were checked individually instead
Japanese jRCT Directly retrieved WJOG14120L (jRCTs051200138) and JCOG1914 (jRCTs031200230) WJOG remains marked Complete; JCOG1914 marked Not Recruiting. Registry target enrollment is not substituted for published actual enrollment
WHO ICTRP / ISRCTN Attempted lung-squamous portal searches ICTRP HTTP 403; ISRCTN redirected to a holding page. Neither produced searchable trial results; international completeness is not claimed
ASCO / ESMO / NICE ASCO living page; ESMO living-page citation metadata and official guideline-news listing; direct NICE NG122 retrieval ASCO HTTP 403. ESMO v1.3 August 2026 verified; September Pan-Asian adaptation announcement recorded without inferring recommendations. NICE still displays update 2024-03-08 and review 2026-02-10; linked appraisals were not comprehensively checked
Burden/statistics portals IARC lung-cancer page, Global Cancer Observatory landing page, NCI SEER Stat Facts and SEER Explorer Added directly verified 2026 US all-lung projections with explicit histology/model limits. Dynamic Explorer did not yield a reproducible table on direct retrieval, so no new LUSC survival number was copied. No new global LUSC burden dataset was selected
Patient organisations GO2 support/stigma; Roy Castle; LUNGevity HOPE Summit and third-quarter trial-initiative reports; LCRF resource page Public LUNGevity material added, mixed lung cancer and organisation-reported. GO2/Roy Castle accessible. LCRF HTTP 403 now marked as an unverified-current-content historical listing
Publishers/full text Lancet, Elsevier and Clinical Lung Cancer/DOI endpoints for selected records No article bodies retrieved. Lancet and Clinical Lung Cancer returned 403; the Elsevier S1914 API returned metadata only despite HTTP 200; DOI redirects were not full texts. No abstract-derived effect size was promoted
CENTRAL / SciELO / LILACS Not searchable Known HTTP 403 access limitations; CENTRAL was not searched. For regional transportability (OQ-26), SciELO and LILACS could not be searched, so no region-wide absence claim is made
Unpaywall Skipped LIFEBANK_CONTACT_EMAIL unset. OpenAlex and DOAJ were not queried

What survived triage.

  1. S1914 phase III publication (Daly 2026, PMID 42702214): catalogued and made a full-text retrieval priority on the early-stage and trials pages. Its live trial record (NCT04214262) is active, not recruiting, with posted results. The posted registry primary-outcome table and the updated publication abstract are different reported analyses; do not merge their estimates. Full-text/cutoff reconciliation is pending. No paper-derived efficacy number or treatment recommendation was added.
  2. Histology-stratified NLST analysis (Fan 2026, PMID 42580153): catalogued, linked from screening and OQ-5, and used to remove the broad “trial datasets have not adequately reported” formulation in D5. This is a relevant publication, not a closed question. Its sensitivity tables, diagnosed-case selection and randomized-population mortality denominators need full-text review before changing any estimate.
  3. Older-adult stage-III JCOG1914 report (Omori 2026, PMID 42636548): bibliography entry and OQ-9 retrieval task only; direct Japanese registry verified. No Japanese NSCLC result was silently generalized to frail LUSC populations.
  4. LUNGevity assessment-schedule working-group recommendations (Guidry 2026, PMID 42501613): bibliography entry and OQ-12 retrieval task; the October organisational report surfaced this earlier-online paper again. Recommendations do not demonstrate improved accrual or completion.

All four additions were checked through both PubMed publication types/linked notices and Crossref updated-by; none was flagged. They bring the bibliography to 347 unique PubMed records. Every newly introduced PMID came from live PubMed E-utilities this session; every newly introduced NCT identifier came from the live registry API. No DOI-only paper survived triage. No deep note was justified without newly retrieved full-text evidence.

Other changes. Corrected the guideline registry's unsupported claim that the without-driver ASCO web page is verified at 2026.3.3. The live indexed without-driver record remains 2026.3.1; 2026.3.3 is verified for the separate with-driver publication. The registry now requires matching driver scope plus version to a retrieved official source and forbids treating a blocked page as version verification. Added ESMO version/announcement metadata, the dated SEER all-histology context row, two public LUNGevity source annotations, and the LCRF access limitation. Updated INDEX statuses. Most preclinical, computational-signature, case-report, protocol and non-squamous hits were not added; the previously rejected Xihu district study still does not establish global burden. Existing AEGEAN/FIND/WJOG entries were not duplicated.

Validation. Mechanical checks found zero broken local links, zero new identifier/provenance failures, no new body/reference mismatch on the three pages adding journal citations, four exact bibliography-title matches to live metadata, and clean dual-source retraction checks for the four additions. Verified 347 bibliography records and seven draft wiki pages. Ten content files plus this append-only log were edited; the sole new condition file is the permitted literature/sweeps/2026-10-17.json. No global generator, publisher, deployment or git command was run. Independent review remains pending; no page was promoted.

Next sweep should chase:

  1. Retrieve full texts and tables for S1914, the Fan NLST re-analysis, JCOG1914, and the trial-assessment recommendations. Prioritize S1914's analysis-cutoff reconciliation and OQ-5's sensitivity/diagnosed-case-versus-randomized-population distinction.
  2. Confirm the current without-driver ASCO web version when official access is available, and retrieve the actual ESMO Pan-Asian adaptation before synthesizing regional recommendations.
  3. Continue HLX43 and 7MW3711 recruitment/results monitoring; TROPION squamous-subgroup reporting; AEGEAN final OS; FIND stage II; and completed successors to the perioperative-immunotherapy and anti-TIGIT Cochrane protocols.
  4. Revisit regional and international registry coverage when ICTRP/ISRCTN/SciELO/LILACS access improves. Keep source-qualified boundaries until then.
  5. Have a different engine audit the October additions and the seven draft wiki pages; KRT13/hillock evidence remains bibliography-only pending that independent prioritization.

2026-10-24 — Periodic literature sweep (Grok)

Author: Grok. This is a literature sweep, not an independent audit. All changed content files carry status: draft and last-curated: 2026-10-24; the log is append-only. Biomarkers joins the seven previously drafted wiki pages, leaving eight canonical pages awaiting a different engine's audit. No treatment recommendation changed and no open question was closed.

Window and searches. Used the requested 2026-08-28 through 2026-10-24 publication-date window. Ran 34 PubMed E-utilities topic searches (one ordinary and one "Cochrane Database Syst Rev"[jour] search for each of the 17 canonical topics) plus six supplementary E-utilities searches (named trials; ASCO living; broad in-window CDSR; Cochrane protocol follow-up; LUSC RCT/phase III; LUSC systematic reviews) and nine follow-up searches (ivonescimab/HARMONi; TROPION/Dato-DXd; ASCO without-driver; S1914; HLX43/7MW3711/zanzalintinib; AEGEAN OS; FIND; ctDNA strategy trials; new guidelines). Query strings, translations, returned IDs and selected-record checks are in the search manifest.

The 17 topic queries plus supplements returned 1,303 unique PMIDs. These are retrieval counts, not a claim of full-text review. Title triage prioritized the 109-hit direct LUSC set (13 new versus the 2026-10-17 sweep), named-trial follow-ups, guidelines, Cochrane, and squamous-relevant registrations. High-recall searches (screening 537; patient-experience 422) included substantial off-topic material.

Sources actually queried and limits.

Source What was done Finding / boundary
PubMed E-utilities 34 topic/CDSR searches, six supplementary searches, nine follow-up searches; ESummary of 1,303 records; EFetch of selected records Six papers selected; no Cochrane lung-cancer treatment review in the window
Cochrane reviews through PubMed CDSR query per topic, plus a broad in-window lung/NSCLC CDSR query and prior-protocol retrieval In-window CDSR hits were menopausal hormone therapy (PMID 42695385) and fetal magnesium neuroprotection (PMID 42689525). Prior protocols PMID 40386901 and PMID 40226904 remain protocols. Plissonneau 2026 (PMID 42440312) already catalogued. An extensive-stage SCLC network meta-analysis (PMID 42578486) is off-scope
Europe PMC REST Four windowed queries (direct LUSC title; LUSC any; CDSR; named-trial terms) Direct-title 46 hits (mostly MEDLINE); LUSC-any 328 (255 MEDLINE, 73 other, including preprints). Named-trial query was too broad (12,478 hits) and was not treated as a completeness claim. No EPMC-only peer-reviewed record was selected
Crossref REST DOI lookup and updated-by on all six added papers All six resolved; no retraction/expression-of-concern update. No owner email sent
ClinicalTrials.gov API v2 Re-fetched all 33 previously cited records; searched new registrations, last-update, and results-first-post in the window Status/enrollment/hasResults matched stored values. NCT04310007 last update 2026-10-22, still non-squamous. NCT05456841 last update 2026-10-07, still recruiting. KEYNOTE-671 still active, not recruiting
ClinicalTrials.gov discovery New squamous/NSCLC registrations and updates Added NCT07756645 (recruiting phase III first-line sqNSCLC, n=940 estimated) and NCT07858253 (not-yet-recruiting phase II ctDNA-guided consolidation, n=43). Most other new hits were non-squamous, pan-solid-tumour, or early-phase
Japanese jRCT Directly retrieved WJOG14120L (jRCTs051200138) and JCOG1914 (jRCTs031200230) WJOG remains Complete; JCOG1914 remains Not Recruiting
WHO ICTRP / ISRCTN / ChiCTR Portal probes ICTRP HTML portal loaded (200) but is JS-driven and produced no programmatic result set. ISRCTN search redirected to a holding page. ChiCTR search returned HTTP 405. International completeness is not claimed
ASCO / ESMO / NICE ASCO living page; ESMO living-page citation metadata; NICE NG122 ASCO HTTP 403. ESMO still v1.3 August 2026. NICE still updated 2024-03-08, last reviewed 2026-02-10
Burden/statistics portals NCI SEER Stat Facts lung and bronchus Same 2026 projections as 17 October: 229,410 new cases; 124,990 deaths; all histologies
Patient organisations GO2 help-line and stigma; LUNGevity; Roy Castle; LCRF how-we-can-help GO2 cited URLs HTTP 200; /for-patients/ now 404. LCRF HTTP 200 after the 2026-10-17 403. No new LUSC-specific campaign
CENTRAL / SciELO / LILACS Not searchable cochranelibrary.com and search.scielo.org HTTP 403. For OQ-26, SciELO and LILACS could not be searched
Unpaywall Skipped LIFEBANK_CONTACT_EMAIL unset. OpenAlex and DOAJ were not queried

Every absence below is an absence in the named source only.

What survived triage.

  1. CheckMate 77T biomarker analysis (Cascone 2026, PMID 42587156). PMC full text (PMC13668692) verified. Biomarker-evaluable subset = 41% of randomized patients. Presurgical ctDNA clearance 66% vs 38%; pCR given clearance 50% vs 12%; 0/25 nivolumab-treated patients without clearance had pCR. Squamous histology was a top machine-learning predictor of prolonged EFS. KEAP1/STK11 mutations were generally non-squamous; CDKN2A mutations generally squamous. Pooled KEAP1/STK11/CDKN2A/SMARCA4 EFS HR 0.48 (0.28–0.83) is mixed histology. → early-stage-and-perioperative-therapy.md, biomarkers.md, STATISTICS, OQ-3, OQ-8.
  2. NCT07756645, recruiting phase III first-line squamous NSCLC, ABBV-1480 plus chemotherapy versus pembrolizumab plus chemotherapy, n=940 estimated, dual primary PFS and OS. First posted 2026-08-10, so the prior sweep's first-posted ≥2026-08-28 filter missed it. The registry does not state the agent's mechanism; a PubMed search for ABBV-1480 returned 0 records, and none was inferred. → clinical-trials-landscape.md.
  3. ESTRO high-dose thoracic reirradiation guideline (Andratschke 2026, PMID 42468604) and STS 2026 sublobar-resection consensus (Khullar 2026, PMID 42320552). Catalogued from abstracts; 42 and 21 statements respectively were not extracted. → guidelines.md, REGISTRY; OQ-18 retrieval task.
  4. CLEAR-Lung III (NCT07858253): not-yet-recruiting phase II, n=43, MRD-clearance primary after chemoradiation. Pipeline only; does not close OQ-8. → trials page, OQ-8.
  5. Bibliography/STATISTICS only: Zhang 2026 central NSCLC surgical conversion after neoadjuvant chemo-IO (PMID 42825882; observational, n=75 operated); Dyrbekk 2026 NFE2L2 and metastatic/brain-metastasis association in resected LUSC (PMID 42909660); Jareebi 2026 Mendelian randomization of smoking intensity on squamous carcinoma (PMID 42888622; FinnGen, 365 cases, OR 5.95 per SD).
  6. LCRF patient hub restored to HTTP 200. GO2 cited URLs remain live.

All six additions were checked through both PubMed publication types/linked notices and Crossref updated-by; none was flagged. They bring the bibliography to 353 unique PubMed records. Every newly introduced PMID came from live PubMed E-utilities this session; every newly introduced NCT identifier came from the live registry API. No DOI-only paper survived triage. No deep note was written: the 77T correlative analysis extends an already-catalogued trial rather than opening a field.

Triaged out (examples): 13 new direct-LUSC titles were almost all preclinical, in silico, or case reports; ivonescimab OS news (PMID 42893518) and EGFR-mutant HARMONi-A (PMID 42636833); SKYSCRAPER-01 TIGIT-negative phase III (PMID 42507968; mixed NSCLC, histology not in the abstract); TROPION-PanTumor04 (NCT07890714); ADC reviews without a LUSC efficacy signal; GO2 /for-patients/ 404 (cited help-line/stigma URLs still resolve). S1914, Fan NLST, JCOG1914, and Guidry assessment-schedule full texts remain unavailable (Lancet 403).

Pages changed (all → status: draft, dated 2026-10-24): biomarkers (demoted from curated); early-stage-and-perioperative-therapy; clinical-trials-landscape; guidelines.

Other files updated: BIBLIOGRAPHY (6 records; 353 total); STATISTICS; REGISTRY; OPEN-QUESTIONS (OQ-2, OQ-3, OQ-8, OQ-18 sharpened; none closed); INDEX; patient-voice sources.md. New file: literature/sweeps/2026-10-24.json.

Next sweep should chase:

  1. Retrieve remaining full texts: S1914 analysis-cutoff reconciliation; Fan NLST histology-specific sensitivity tables; JCOG1914 histology/fitness/QoL tables; STS sublobar statements; ESTRO reirradiation statements; ESMO Pan-Asian adaptation.
  2. Confirm the current without-driver ASCO web version when official access is available.
  3. ABBV-1480 (NCT07756645) mechanism, recruitment, and results; HLX43 and 7MW3711; TROPION squamous subgroups; AEGEAN final OS; FIND stage II; CLEAR-Lung III activation; Cochrane protocol successors (PMID 40386901, PMID 40226904).
  4. Revisit ICTRP/ISRCTN/ChiCTR/SciELO/LILACS when access improves. Keep source-qualified boundaries until then.
  5. Have a different engine audit the October additions, now including biomarkers. KRT13/hillock evidence remains bibliography-only.